Curve Therapeutics is a biopharmaceutical company focused on revolutionizing drug discovery through its intracellular screening platform to develop innovative therapeutics for challenging disease targets, particularly in the field of cancer.

Curve Therapeutics

Johnson & Johnson develops and manufactures healthcare products and provides related services, focusing on pharmaceuticals, medical devices, and consumer packaged goods. The company has been operating for more than 135 years in the healthcare sector.

Johnson & Johnson

Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged.
 
Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes.
 
We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.

Hard to believe it’s been a week already since my short, but excellent trip to Australia. A big thank you to the organisers of the International Peptide Symposium and the Australian Peptide Conference for the invitation to present research from the Tavassoli lab (University of Southampton) and Curve Therapeutics in Brisbane last week.

I really enjoyed reconnecting with peptide colleagues from around the world and hearing about all the latest exciting research in the peptide field. It was a fantastic touch by the organisers to give us the opportunity to meet the local wildlife during a conference lunch break.

Also, I am a Partner Investigator at the Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS), and really enjoyed the opportunity to reconnect with the CIPPS team, and to hear about all the excellent research arising from CIPPS. 

All in all, a fantastic few days that have left their mark: I've been singing Men at Work's Down Under since my return...

We’re #hiring a new Senior Scientist – Microfluidics in Southampton, England. Apply today or share this post with your network.

We are thrilled to welcome Dr Monika Ermann as our VP of Drug Discovery, and Profs. Julian Downward and Steven Benkovic to our Scientific Advisory Board. 

With our new facilities at Southampton Science Park, we are well positioned to expand our capabilities from the development of our Microcycle™ platform to the discovery of new drugs. 

https://lnkd.in/ePvCkBXY

Metric
Company Name	Curve Therapeutics	Johnson & Johnson
Symbol
MSH ID	COM:CURVETX	UK:CO:JNJ
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biopharmaceuticals	Healthcare and Medical Products
Country	GB	UK
Stage	Series A
Employee Count	17
Website	curvetx.com	jnj.co.uk
LinkedIn	curve-therapeutics-limited	johnson-&-johnson
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	105
Web Traffic Growth	-0.97
Valuation
Raised Capital	51.36M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CURVETX

Curve Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue